Canaccord Genuity Downgrades Inari Medical to Hold, Raises Price Target to $80

Benzinga · 01/07 11:17
Canaccord Genuity analyst William Plovanic downgrades Inari Medical (NASDAQ:NARI) from Buy to Hold and raises the price target from $74 to $80.